For people younger than 65, U.S.-licensed flu vaccines had an estimated effectiveness of 44% to 54% that season. Among those who completed a 6-month follow-up, the mRNA vaccine had a relative efficacy ...

According to health department officials, the person is the first to be infected with influenza A H5, an avian flu. The risk ...

The new trial, funded by Pfizer, compared the company’s mRNA shot to Fluzone, one of the most widely used seasonal flu ...

For the last several months, reports about bird flu have largely quieted -- until now. In the first human bird flu case in the U.S. since February, an older adult in Washington state was hospitalized ...

The mRNA platform offers the advantage of faster vaccine production, which could allow more time to decide on which flu strains to cover.